Genen­tech vet Troy Cox named Foun­da­tion Med CEO; Mo­men­ta inks a $600M col­lab­o­ra­tion deal

• Troy Cox, the se­nior VP of on­col­o­gy sales and mar­ket­ing at Genen­tech, is leav­ing the big Roche sub­sidiary to take the CEO’s job at Foun­da­tion Med­i­cine $FMI. Long­time CEO Michael Pelli­ni is tak­ing the chair­man’s post as Alex­is Borisy stays on the board.

• Mo­men­ta Phar­ma­ceu­ti­cals $MN­TA is part­ner­ing with Aus­tralia’s CSL on the de­vel­op­ment and com­mer­cial­iza­tion of Fc mul­ti­mer pro­teins, in­clud­ing Mo­men­ta’s M230. Mo­men­ta gets $50 mil­lion up front and a shot at up to $550 mil­lion in mile­stones. “This col­lab­o­ra­tion and li­cense agree­ment with CSL val­i­dates our be­lief that M230 is an ex­cit­ing re­com­bi­nant prod­uct can­di­date for po­ten­tial use in au­toim­mune in­di­ca­tions. It was de­vel­oped us­ing our pro­pri­etary Fc bi­ol­o­gy plat­form and un­der­stand­ing of how in­tra­venous im­munoglob­u­lin (IVIg) works in au­toim­mune dis­eases,” said Mo­men­ta CEO Craig A. Wheel­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER